🟢 NeoGenomics is trading 11.1% up today on Q2 earnings beat and raised FY26 guidance

NeoGenomics is trading 11.1% up at $14.89 in pre-market following a strong second-quarter earnings report that beat revenue and EPS estimates.

• The company returned to profitability and raised its full-year 2026 revenue and adjusted EBITDA guidance.
• Management highlighted robust growth in higher-value NGS clinical services, supported by positive sentiment across the healthcare sector.